These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 28840400)
1. Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease. Petta V; Perlikos F; Loukides S; Bakakos P; Chalkias A; Iacovidou N; Xanthos T; Tsekoura D; Hillas G Heart Fail Rev; 2017 Nov; 22(6):753-763. PubMed ID: 28840400 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities. Corrao S; Brunori G; Lupo U; Perticone F Eur Respir Rev; 2017 Sep; 26(145):. PubMed ID: 28794142 [TBL] [Abstract][Full Text] [Related]
3. Commencement of cardioselective beta-blockers during hospitalisation for acute exacerbations of chronic obstructive pulmonary disease. Neef PA; Burrell LM; McDonald CF; Irving LB; Johnson DF; Steinfort DP Intern Med J; 2017 Sep; 47(9):1043-1050. PubMed ID: 28608512 [TBL] [Abstract][Full Text] [Related]
4. Impact of selective and nonselective beta-blockers on the risk of severe exacerbations in patients with COPD. Huang YL; Lai CC; Wang YH; Wang CY; Wang JY; Wang HC; Yu CJ; Chen L Int J Chron Obstruct Pulmon Dis; 2017; 12():2987-2996. PubMed ID: 29066880 [TBL] [Abstract][Full Text] [Related]
5. Beta-blockers in COPD: time for reappraisal. Lipworth B; Wedzicha J; Devereux G; Vestbo J; Dransfield MT Eur Respir J; 2016 Sep; 48(3):880-8. PubMed ID: 27390282 [TBL] [Abstract][Full Text] [Related]
6. Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease. Buhl R; Magder S; Bothner U; Tetzlaff K; Voß F; Loaiza L; Vogelmeier CF; McGarvey L Respir Med; 2017 Jan; 122():58-66. PubMed ID: 27993292 [TBL] [Abstract][Full Text] [Related]
7. Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease. Onishi K J Cardiol; 2017 Aug; 70(2):128-134. PubMed ID: 28325523 [TBL] [Abstract][Full Text] [Related]
8. [Controversies and dilemmas on the use of beta-blockers in treatment of associated cardiovascular disease in patients with chronic obstructive pulmonary disease]. Pescaru C; Tudorache V; Oancea C Pneumologia; 2010; 59(1):27-30. PubMed ID: 20432790 [TBL] [Abstract][Full Text] [Related]
9. Inhaled Long-Acting β2-Agonists Do Not Increase Fatal Cardiovascular Adverse Events in COPD: A Meta-Analysis. Xia N; Wang H; Nie X PLoS One; 2015; 10(9):e0137904. PubMed ID: 26378450 [TBL] [Abstract][Full Text] [Related]
10. The role of beta-blockers in the management of chronic obstructive pulmonary disease. Leitao Filho FS; Alotaibi NM; Yamasaki K; Ngan DA; Sin DD Expert Rev Respir Med; 2018 Feb; 12(2):125-135. PubMed ID: 29258360 [TBL] [Abstract][Full Text] [Related]
11. Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease. Zeng LH; Hu YX; Liu L; Zhang M; Cui H Clin Interv Aging; 2013; 8():1157-65. PubMed ID: 24072964 [TBL] [Abstract][Full Text] [Related]
12. The burden of chronic obstructive pulmonary disease associated with maintenance monotherapy in the UK. Edwards SC; Fairbrother SE; Scowcroft A; Chiu G; Ternouth A; Lipworth BJ Int J Chron Obstruct Pulmon Dis; 2016; 11():2851-2858. PubMed ID: 27920512 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological modulation of beta-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure. Matera MG; Martuscelli E; Cazzola M Pulm Pharmacol Ther; 2010 Feb; 23(1):1-8. PubMed ID: 19833222 [TBL] [Abstract][Full Text] [Related]
14. β-Blockers and the Rate of Chronic Obstructive Pulmonary Disease Exacerbations. Mersfelder TL; Shiltz DL Ann Pharmacother; 2019 Dec; 53(12):1249-1258. PubMed ID: 31271049 [No Abstract] [Full Text] [Related]
16. Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Salpeter SR; Ormiston TM; Salpeter EE; Poole PJ; Cates CJ Respir Med; 2003 Oct; 97(10):1094-101. PubMed ID: 14561016 [TBL] [Abstract][Full Text] [Related]
17. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design. Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416 [TBL] [Abstract][Full Text] [Related]
18. Symptom variability and control in COPD: Advantages of dual bronchodilation therapy. Di Marco F; Santus P; Scichilone N; Solidoro P; Contoli M; Braido F; Corsico AG Respir Med; 2017 Apr; 125():49-56. PubMed ID: 28340862 [TBL] [Abstract][Full Text] [Related]
19. The reasons for triple therapy in stable COPD patients in Japanese clinical practice. Miyazaki M; Nakamura H; Takahashi S; Chubachi S; Sasaki M; Haraguchi M; Terai H; Ishii M; Fukunaga K; Tasaka S; Soejima K; Asano K; Betsuyaku T; Int J Chron Obstruct Pulmon Dis; 2015; 10():1053-9. PubMed ID: 26082629 [TBL] [Abstract][Full Text] [Related]
20. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes. Hizawa N Int J Chron Obstruct Pulmon Dis; 2015; 10():1093-102. PubMed ID: 26089659 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]